24/7 Market News Snapshot 26 September, 2025 – Fractyl Health, Inc. Common Stock (NASDAQ:GUTS)

September 26, 2025

DENVER, Colo., 26 September, 2025 (www.247marketnews.com) – (Nasdaq:GUTS) are discussed in this article.
Fractyl Health, Inc. (Nasdaq:GUTS) is experiencing a remarkable surge in investor interest, with its stock price jumping 22.48% to $1.237 in pre-market trading, following an announcement of significant findings from its REMAIN-1 Midpoint Cohort study. The increased trading volume of 6.16 million shares reflects a growing confidence in the company’s future, particularly in light of its innovative therapeutic approach.

The REMAIN-1 study highlights the efficacy of Fractyl’s Revita treatment in maintaining weight loss after patients discontinue GLP-1 medications, such as tirzepatide. This pilot study included 45 participants who lost substantial weight on the medication, demonstrating a further 2.5% reduction in total body weight over three months with Revita treatment, while those not receiving Revita experienced a concerning 10% weight regain.

These compelling results position Revita as a potential lifesaving solution for individuals facing the challenges of weight maintenance, exhibiting promising safety and tolerability. Dr. Shelby Sullivan from the Geisel School of Medicine emphasized the significance of these findings in addressing long-term weight regain, a prevalent issue attributed to the costs and side effects associated with current medications.

Fractyl Health is advancing its pivotal study towards completion, with comprehensive data expected in early 2026, underscoring its commitment to developing first-in-class interventions for obesity management. As Fractyl navigates this critical phase, the prospect of Revita reshaping treatment paradigms for obesity and type 2 diabetes comes into sharper focus, marking a transformative moment in metabolic disease management strategy.

Related news for (GUTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.